LCM
CBAY

Laurion Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Laurion Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-214,356
Closed -$2.35M – 720
2023
Q2 		$2.35M Sell
214,356
-1,707,747
-89% -$15.9M 0.01% 310
2023
Q1 		$16.8M Buy
1,922,103
+306,203
+19% +$2.45M 0.11% 163
2022
Q4 		$10.1M Hold
1,615,900
– – 0.05% 225
2022
Q3 		$5.66M Buy
1,615,900
+40,631
+3% +$146K 0.03% 243
2022
Q2 		$4.65M Buy
+1,575,269
New +$3.76M 0.07% 170
2018
Q2 		– Sell
-50,560
Closed -$657K – 1646
2018
Q1 		$657K Buy
+50,560
New +$628K 0.01% 952

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Laurion Capital Management's CBAY Position: Q3 2023 in Review

Laurion Capital Management sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 214,356 shares — an estimated $2.35M sold.

Laurion Capital Management first reported a position in CBAY in Q1 2018 and held it in 6 quarters. The position peaked at $16.8M in Q1 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

  • Laurion Capital Management reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Laurion Capital Management sold 214,356 Cymabay Therapeutics shares in Q3 2023, an estimated $2.35M.
  • Laurion Capital Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 6 quarters.
  • Laurion Capital Management's Cymabay Therapeutics position peaked at $16.8M in Q1 2023.
  • 189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.